Related by context. All words. (Click for frequent words.) 68 Anti Tumor 68 HDAC Inhibitor 68 Preclinical Data 68 Kinase Inhibitor 67 Present Preclinical Data 67 Poster Presentations 66 Vaccine Adjuvant 66 Systemic Delivery 66 Presents Preclinical Data 65 Small Molecule 65 Recombinant Human 65 Clinical Trial Results 65 Shows Promising 65 Preclinical Study 65 Dendritic Cells 65 Advanced Renal Cell 64 Prolongs Survival 64 Antiviral Activity 64 Pharmacyclics Announces 64 Reports Preclinical Data 64 Study Evaluating 64 Completes Patient Enrollment 64 Therapeutic Targets 64 Sangamo BioSciences Announces 64 See CLINICAL PHARMACOLOGY 64 Oligonucleotides 63 Aethlon Medical Releases 63 Antitumor Activity 63 Oral Fingolimod 63 Pooled Analysis 63 Late Breaker 63 Autoimmune Disease 63 Novel Oral 63 Antisense 63 Immunotherapeutic 63 Initiates Clinical Trial 63 RNAi Therapeutics 63 Anthrax Toxin 63 Emerging Therapies 63 Submits NDA 63 Diabetic Nephropathy 62 Placebo Controlled Trial 62 BiTE Antibody 62 Bazedoxifene 62 Clinical Trial Data 62 Selective Cardiac Myosin 62 Monoclonal Antibodies 62 FOLOTYN ® 62 RNAi Therapeutic 62 RNA Interference 62 Protein Expression 62 pralatrexate injection folate analogue 62 Tyrosine Kinase Inhibitor 62 Oral Presentations 62 Phase 2b Clinical Trial 62 Osteoporosis Treatment 62 Presents Preclinical 62 NDA Submission 62 Files IND 62 Diabetic Neuropathy 62 Shows Promise Against 62 Autoimmune Diseases 61 Liver Toxicity 61 Elagolix 61 Hormone Receptor Positive 61 IND Filing 61 Complicated Skin 61 Pharmacokinetic Study 61 Hsp# Inhibitor 61 Double Blind Placebo 61 Advanced Melanoma 61 Cancer Vaccines 61 Announces Poster Presentations 61 Combination REOLYSIN R 61 Randomized Double Blind 61 Meta Analysis 61 Phase 2a Trial 61 Demonstrates Significant 61 Targeted Therapies 61 Nuvelo Announces 61 Metastatic Melanoma 61 HuCAL GOLD R 61 Regenerative Cells 61 Chronic Hepatitis C 61 Hepatocellular Carcinoma 61 Novel Approaches 61 Mg Usa 61 Completes Enrollment 61 Demonstrates Positive 61 Liposomal 61 Hepatic Encephalopathy 60 Therapeutic Vaccines 60 Anticancer Drugs 60 Controlled Trial 60 Adjuvant Chemotherapy 60 Phase 2b Trial 60 PI3K/mTOR 60 Clinical Outcome 60 Initiate Clinical Trial 60 Valopicitabine 60 Maven Semantic 60 small molecule agonists 60 Receives Orphan Drug Designation 60 Immunomedics Announces 60 Receives Orphan Drug 60 PUBMED 60 Antiviral Therapy 60 Initiates Phase II 60 Patient Enrollment 60 Protease Inhibitor 60 CYT# potent vascular disrupting 60 Initiates Enrollment 60 website www.lipidsciences.com 60 Meets Primary Endpoint 60 samarium Sm 60 Adjuvant Treatment 60 entitled Synergistic 59 #th Annual Interscience 59 TÎ ² 4 59 Initiates Clinical 59 Randomized Double blind 59 Skin Lesions 59 Phase IIb Clinical Trial 59 Autologous Stem Cell Transplantation 59 #nd EORTC NCI 59 Phase IIb Trial 59 Phase III Clinical Trial 59 Patients Treated With 59 Selective Electrochemical Tumor Ablation 59 visit www.LifeVantage.com 59 Dose Response 59 www.telik.com 59 Chronic Lymphocytic Leukemia CLL 59 Medullary Thyroid Cancer 59 Presents Positive 59 Nasdaq QGEN 59 WEB OF SCIENCE 59 Pharmacokinetics PK 59 Biological Therapy 59 Polymerase Inhibitor 58 HCV Protease Inhibitor 58 Gout Drug 58 Abstract Accepted 58 www.pranabio.com 58 Lupus Drug 58 non nucleoside inhibitor 58 Inc. Nasdaq IMGN 58 Romidepsin 58 J Allergy Clin 58 ARRY # 58 novel VDA molecule 58 Phase IIa Clinical Trial 58 novel histone deacetylase 58 Severe Sepsis 58 Xcytrin R 58 Upregulation 58 ID NCT# 58 Hormone Refractory Prostate Cancer 58 Adjunctive Therapy 58 Innate Immunity 58 Bruton tyrosine kinase 58 Prostate Cancer Patients 58 Vascular Targeting Agents 58 targeting CD# 58 Investigational Drug 58 AVI BioPharma Announces 58 Relapsing Multiple Sclerosis 58 Parathyroid Hormone 58 Pafuramidine 58 Randomized Double Blind Placebo 58 Clostridium difficile Infection 58 Upcoming Presentations 58 selective kinase inhibitor 58 CYP#A# CYP#D# 58 pan HDAC inhibitor 58 Milestone Payment 58 www.syntapharma.com 58 Full Prescribing Information 58 mGluR5 negative 58 Refractory Hodgkin Lymphoma 58 Biologic Therapy 58 LWLG 58 Therapeutic Competitors companiesandmarkets.com adEgemonye 58 TLR antagonists 58 Lenocta 58 SPL# Gel vaginal microbicide 58 MBRX 58 hypereosinophilic syndrome 58 Prospective Randomized 58 2 inhibitor CYT# 58 sorafenib tablets 58 FDA APPROVES 58 Lowering Blood Pressure 58 Therapy Evaluation 58 Antigen Specific 58 lexidronam injection 58 oral prodrug 57 #th Interscience Conference 57 Pivotal Phase III 57 www.vioquestpharm.com 57 Orthop Surg 57 CCX# 57 Catheter Associated 57 Anti CD# Antibody 57 Migraine Drug 57 targeted antifolate 57 Pivotal Phase 57 Pivotal Study 57 Randomized Controlled Trials 57 vapreotide acetate 57 Randomized Trials 57 Dose Escalation 57 visit www.sanofi aventis.us 57 www.cougarbiotechnology.com 57 Secondary Hyperparathyroidism 57 Chronic Lymphocytic Leukemia 57 AASLD Meeting 57 Ranolazine 57 Preclinical Models 57 Randomized Phase 57 ON #.Na 57 PNP inhibitor 57 AAG geldanamycin analog 57 AACR NCI EORTC 57 HCV polymerase inhibitors 57 Power3 Alzheimer disease 57 Soft Tissue Sarcoma 57 NASDAQ IDRA 57 Postdoctoral Position 57 Tumor Microenvironment 57 Arch Neurol 57 www.vical.com 57 ThermoDox ® clinical 57 Percutaneous Tibial Nerve Stimulation 57 Phase 2b Study 57 orally administered inhibitor 57 www.vicortech.com 57 Molecular Cancer 57 ORAL Sync 57 Biologic Drugs 57 Spectrum Pharmaceuticals Announces 57 www.rosettabio.com 57 Bioral ® 57 BiTE R 57 selective inhibition 57 Panzem NCD 57 www.regenerx.com 57 DNA methyltransferase inhibitors 57 Bladder Cancer 57 oral proteasome inhibitor 56 R lenalidomide 56 trastuzumab DM1 T DM1 56 II Clinical Trial 56 LibiGel ® 56 Announce Collaboration Agreement 56 oncolytic virus therapies 56 IL# PE#QQR 56 Blinatumomab 56 Achieves Primary Endpoint 56 Therapeutics Roundtable 56 Schizophrenia Treatment 56 doi #.#/fj.#-# 56 Sipuleucel T 56 Randomized Phase II 56 Environ Health Perspect 56 www.micromet inc.com 56 visit www.dobimedical.com 56 J Am Coll 56 Plaque Psoriasis 56 Fondaparinux 56 Naive Patients 56 Tumor Response 56 Bone Metastases 56 Talabostat 56 Visit Adeptron 56 Projected Release Date 56 Ann Rheum Dis 56 MEK inhibitors 56 antimitotic 56 http:/www.marinabio.com 56 Outpatient Setting 56 Successfully Completes Phase 56 Cell Transplant 56 programs visit http:/www.bionovo.com 56 Stent Implantation 56 Systemic Sclerosis 56 Phase Ib Clinical Trial 56 candidate CRLX# 56 NASDAQ CYTK announced 56 Carfilzomib 56 Brentuximab Vedotin SGN 56 mertansine 56 ALN TTR 56 ABLYNX 56 Luminex Corporation 56 AACR San Antonio 56 TLK# 56 ThermoDox R 56 AACR symposium 56 uricase 56 motexafin gadolinium Injection 56 http:/www.vical.com 56 MAGE A3 ASCI 56 kidney urologic 56 Venous Thromboembolism 56 IN PATIENTS WITH 56 PEG SN# 56 antibody blinatumomab MT#/MEDI-# 56 PPD Declares 56 TO AVOID PREGNANCY WHILE 56 OTCBB AOLS 56 www.ixsbio.com 56 Novel Inhibitor 56 MRNJ 56 Cell Lymphoma 56 R roscovitine 56 Intravascular 56 Panzem R 56 HCV NS5B polymerase 56 Cell Lung Cancer 56 BUPHENYL R 56 Nasdaq IDRA today 56 Targanta Therapeutics Corporation 56 www.marshalledwardsinc.com 56 evaluating tivozanib 56 Telik logo TELINTRA 56 histone deacetylase HDAC inhibitor 56 MGd 56 LENALIDOMIDE 56 endometriosis ovarian cysts 56 bazedoxifene conjugated estrogens 55 NEUGENE R 55 www.sanofi aventis.us 55 Controlled Release 55 Hepatotoxicity 55 Bortezomib 55 ALN HPN 55 Demonstrates Sustained 55 MEK inhibitor 55 HCV protease 55 dependent kinase inhibitor 55 www.flutest.com 55 Angiogenesis 55 Inc. Nasdaq AVRX 55 Neoplasia 55 Traficet EN 55 Nasdaq PPHM 55 Flamel Technologies Announces 55 www.gene.com 55 Taro Receives 55 gastrointestinal stromal tumors GIST 55 Phase 1b Clinical Trial 55 Granted Orphan Drug 55 Cancer Therapeutic 55 regarding Aethlon Medical 55 Initiates Phase III 55 MT#/MEDI-# 55 By JAMAAL ABDUL 55 See WARNINGS 55 ENMD # 55 J Am Acad 55 www.nymox.com email info@nymox.com 55 Randomized Clinical Trial 55 Surgical Treatment 55 www.durect.com 55 Physiology Seminar 55 PKC# 55 R MSCRAMM 55 fosbretabulin 55 Hedgehog Pathway Inhibitor 55 bevacizumab Avastin ® 55 www.royalcaribbean.com www.celebrity.com www.pullmAhmed Hilles clan 55 First Patient Treated 55 xenograft models 55 Autoimmunity 55 RNAi therapeutic targeting 55 refractory chronic lymphocytic 55 Trastuzumab DM1 55 http:/www.optimerpharma.com 55 = document.location.protocol 55 Accelr8 Announces 55 MKC# MKC# PP 55 Neulasta ® 55 pan histone deacetylase 55 visit www.quidel.com www.colorectal 55 GLOBE NEWSWIRE Cyclacel Pharmaceuticals 55 proteasome inhibitor 55 EXPAREL ™ 55 Diabetic Foot Ulcer 55 Free Full Text 55 acetonide FA 55 PRESENTED AT 55 Cancer Immunotherapy 55 non nucleoside HCV 55 Arch Otolaryngol Head 55 FROM THE COMPANY 55 delafloxacin 55 www.polymedix.com 55 PDX pralatrexate 55 vinca alkaloid 55 MONSTERSTOX.COM Monsterstox.com 55 First Patient Enrolled 55 Inhalation Solution 55 AACR Meeting 55 Am J Obstet 55 www.pharsight.com 55 www.cerus.com 55 www.artesmedical.com 55 biosciences.com 55 myelodysplastic myeloproliferative diseases 55 intravesical infusion therapy 55 Patented Technology 55 novel peptides 54 -Metevier 54 interstitial cystitis IC 54 Webcast Presentations 54 antitumoral 54 www.bdal.com 54 EORTC NCI 54 Initiate Phase 54 Trial Evaluating 54 Phase III Pivotal 54 poly ADP ribose polymerase 54 www.investorfile.com 54 hyaluronidase enzyme 54 #:#-# [023] 54 Boxed Warnings 54 Presents Positive Preclinical 54 JAK1 54 download MIV Therapeutics 54 Tanespimycin 54 PRNewswire FirstCall Bionovo 54 AACR #st Annual Meeting 54 SABCS 54 NOVAVAX 54 metastatic neuroendocrine tumors 54 http:/www.pharsight.com 54 Receives NASDAQ 54 J Pediatr 54 antibody MT# 54 Acute Ischemic Stroke 54 Child Adolesc Psychiatry 54 oral JAK1 54 Randomized Phase III 54 Taglich Brothers Initiates Coverage 54 NASDAQ CXSP announced 54 http:/www.unigene.com 54 FASEB J. 54 PRN8 54 www.chembio.com 54 #:#-# [033] 54 INSPIRE Trial Phase III 54 Patient Enrolment 54 Initiates Phase 2b 54 Clinical Trial Evaluating 54 Proc Am Soc 54 Contraindications 54 www.adeonapharma.com 54 please visit www.advaxis.com 54 Biodefense Vaccines 54 aripiprazole Abilify 54 www.verichipcorp.com 54 Commences Phase 54 identifier NCT# 54 Prodarsan R 54 Largest Database 54 recurrent metastatic ovarian cancer 54 Please visit www.ntt.com 54 Confirmatory Phase 54 number NCT# ClinicalTrials.gov 54 TriCo Bancshares Announces 54 MetaDrug TM 54 Epeius Biotechnologies Corporation 54 ASH Annual Meeting 54 proteasome inhibitors 54 Obstet Gynecol 54 Arch Pediatr Adolesc Med 54 PremierWest Bancorp Announces 54 Immunology Annual Meeting 54 Frankfurt XMP 54 Poster Discussion 54 Hagop M. 54 ACR ARHP 54 rPA Anthrax Vaccine 54 Chronic HCV 54 PATENT FOR 54 ASCO GI 54 evaluating mipomersen 54 Dermatol 54 WHO TOOK 54 Antibody Therapeutics 54 IOVS 54 http:/www.orexigen.com 54 http:/www.mdrnainc.com 54 http:/www.genmab.com 54 PRAECIS PHARMACEUTICALS INCORPORATED 54 Veronate R 54 PRN4 54 ICAAC IDSA 54 information visit www.axa 54 www.ziopharm.com 54 metastatic malignant 54 Phase III Trial 54 http:/www.curagen.com 54 Embolic Protection Device 54 www.inovio.com 54 Oral Presentation 54 Clinical Trials Update 54 ECCMID 54 Inc. Nasdaq OXGN 54 THERAPEUTICS 53 Provides Update Regarding 53 Inflammatory Bowel Diseases 53 Vicor Technologies 53 www.qiagen.com goto 53 vascular disrupting agents 53 PRN3 53 CrossRef Medline 53 http:/www.gpc-biotech.com 53 http:/www.idenix.com 53 Pyridorin TM 53 Visit GITA 53 AACR IASLC Joint 53 discussed NuroPro Power3 53 transthyretin TTR mediated amyloidosis 53 Risk Stratification 53 www.oxigene.com 53 CrossRef Web 53 Cancers Symposium 53 LungAlert TM 53 PLEASE READ THE FOLLOWING 53 Computed Tomographic 53 Habersham Bancorp Announces 53 www.micromet.com 53 http:/www.unitedfamilyhospitals.com 53 www.criticalpath.net 53 www.celsion.com 53 www.bio rad.com 53 immunoregulation 53 #-# Full Text 53 Adventrx Pharmaceuticals Inc 53 CROI 53 IMiDs R 53 nd Annual Meeting 53 atrasentan 53 GSK # 53 www.niddk.nih.gov 53 By JENNIFER LEARN 53 http:/www.ariad.com 53 Int J Radiat Oncol 53 Kaydon Corporation Announces 53 depsipeptide 53 Dose Ranging 53 PRN1 53 Peer Reviewed Journal 53 www.entechsolar.com 53 ICAAC 53 pharma.com 53 Enhances User Experience 53 www.syneron.com 53 BiTE ® 53 www.delcath.com 53 www.sembiosys.com 53 Inc. OTCBB LPTN 53 http:/www.nastech.com 53 Cancer Incidence Mortality 53 Molecular Origins 53 Therapeutic Approaches 53 Endocrinol Metab 53 #:#-# [020] 53 Cambridge Healthtech Institute 53 Bendavia 53 www.ltx.com 53 Clinical Evaluation 53 Cochrane Database Syst Rev 53 Cellceutix web 53 Aplidin R 53 Poniard Pharmaceuticals Announces 53 #:#-#,# [003] 53 IMC A# 53 mGlu2 3 53 Azedra 53 EpCAM 53 Enzo Biochem Reports 53 FULL PRESCRIBING INFORMATION 53 Announces Presentation 53 http:/www.staar.com 53 Elvitegravir 53 www.migenix.com 53 Phase #b/#a clinical 53 LHRH receptor positive 53 CEQ# 53 Poster Presentation 53 Visit BJ Restaurants 53 Augment ™ 53 cisplatin gemcitabine 53 www.appliedbiosystems.com 53 AEG# 53 www.accentia.net 53 Targeted Anticancer Therapies 53 Two Upcoming Investor 53 Molecular Targets 53 www.protus.com 53 Antigen Express website 53 J Clin 53 Matrix Phase 2b 53 compound AEZS 53 NanoMarkets Announces 53 www.oncolyticsbiotech.com 53 darinaparsin ZIO 53 www.connectyx.com 53 Guanilib 53 histone deacetylase HDAC 53 GVAX ® 53 Oncogene 53 ACADIA maintains 53 SAR# [004] 53 Ampligen ® 53 NASDAQ PCYC 53 www.aryx.com 52 Unstable Angina 52 RGB # 52 CENTERS FOR DISEASE CONTROL 52 Chronic Heart Failure 52 Cardiol 52 radezolid 52 Nephrol Dial Transplant 52 Canaccord Adams Hepatitis C 52 Randomized Clinical Trials 52 Suppl. 52 Topline Results 52 prostate cancer mCRPC 52 PHARM 52 Motley Fool www.fool.com Streetevents 52 www.iconplc.com 52 www.uct.com 52 OTCBB SLAT 52 Multicenter Phase 52 www.alexionpharma.com 52 Webcast Scheduled 52 Virco Announces 52 ligand TRAIL 52 HDL Mimetic Peptide 52 ASBMR 52 CARDIOVASCULAR 52 lenalidomide Revlimid R 52 Employment Inducement Awards 52 ABOUT YOUR JOB 52 Dose Ranging Study 52 Enhanced Version 52 visit http:/www.ininc.us 52 ANN INTERN MED 52 Latest Trends 52 BIOLASE Announces 52 COLLABORATION WITH 52 Eur J Endocrinol 52 preclinical efficacy 52 www.adventrx.com 52 Vascular Disrupting Agent 52 SUPERVILLE 52 Curaxin 52 www.vivus.com 52 www.ses newskies.com 52 AASLD 52 www.givenimaging.com 52 www.sanofi aventis.com 52 AAEP Convention 52 PET FROM 52 BZL# 52 resolvin 52 brivanib 52 www.caliperLS.com 52 http:/www.ncbi.nlm.nih.gov/pubmed/# 52 OR CONTENT CONTAINED THEREIN 52 #:# -# [004] 52 PI3K/Akt pathway inhibitor 52 Acute Treatment 52 PCK# 52 neratinib 52 Archexin 52 ZFP Therapeutic 52 www.lca vision.com 52 LMI Aerospace Announces 52 Abstract Full Text 52 via Yahoo www.yahoo.com 52 Nasdaq BNVI 52 Nasdaq EMIS 52 MEDTOX Scientific Announces 52 www.questcor.com 52 www.AMCORE.com 52 anti amnesic 52 Panzem 52 huC# DM4 52 Pivotal Trial 52 www.kla tencor.com 52 http:/www.cambrex.com 52 Tesmilifene 52 Genta Incorporated OTCBB GETA 52 ganetespib 52 Webcast Discussion 52 Visit DataCert 52 Nat Genet 52 AACR Symposium 52 Insteel Industries Announces 52 Nasdaq SGMO announced 52 PSMA ADC 52 Abstract Number 52 XPEL Announces 52 Malignant Mesothelioma 52 contacting COADE 52 subheading Webcasts 52 Upcoming Milestones 52 www.udetection.com 52 DOCUMENTS BECAUSE THEY CONTAIN 52 ID Seq 52 Syndr 52 IN COMBINATION WITH 52 Preclinical Development 52 J Biol Chem 52 vivo efficacy 52 Upcoming Presentation 52 www.multimediagames.com 52 #:#-# [035] 52 WHEN YOU CAN DO 52 J Acquir Immune Defic 52 www.osteologix.com 52 www.holliseden.com 52 www.maxygen.com 52 www.Navistar.com newsroom 52 panobinostat 52 Nasdaq SNSS 52 alpha7 52 BY ALICIA PQ 52 BOCX 52 www.targacept.com 52 Wizzard Software Announces 52 Prospective Multicenter 52 Encision Reports 52 Zoledronic acid 52 PUBLISHED ON 52 immunotherapeutic agent 52 www.gpc biotech.com 52 Clinical Practice Guideline 52 Adnectin 52 INCB# [001] 52 http:/news.xerox.com 52 Pluristem Therapeutics 52 www.insmed.com 52 www.gita.org 52 ASCO GU 51 Nanophase Announces 51 Investigational Device 51 Hematology Meeting 51 PROVENGE ® 51 induces apoptosis 51 http:/www.atherogenics.com 51 Peripheral Arterial 51 ENDO 51 www.cellgenesys.com 51 Upcoming Conferences 51 Therapeutics TCT scientific 51 http:/www.pharmacopeia.com 51 Palatin Technologies website 51 ISSI Announces 51 Proxy Proposals 51 Whole Genome Sequencing 51 www.hythiam.com 51 ASMS Conference 51 MT# MEDI 51 HDL Selective Delipidation 51 #:#-# [007] 51 Upcoming BIO 51 kurstaki 51 www.opexatherapeutics.com 51 Topics Covered I. INTRODUCTION 51 http:/www.durect.com 51 Epiphany Biosciences 51 NASDAQ LIPD 51 #:#-# [006] 51 JAK2 inhibitor 51 J.P. Morgan Healthcare 51 toenail onychomycosis 51 Testosterone MDTS R 51 REPORTS RECORD 51 Undisclosed Investors 51 GeoMet Announces 51 www.labopharm.com 51 www.halozyme.com 51 www.interscience.wiley.com 51 www.biosantepharma.com 51 Southwall Announces 51 Innovium Announces 51 ASGCT 51 concerning Chemtura 51 Annual ICAAC 51 www.cticseattle.com 51 TVIPF 51 Hematologic Malignancies 51 isoform selective 51 Nephrol 51 ongoing Phase 1b 51 ASM Biodefense 51 www.aidshealth.org 51 Exelixis XL# 51 star.edu.sg 51 Brussels GLPG 51 Observational Study 51 www.stemcellthera.com 51 PSORIASIS 51 Semafore Pharmaceuticals 51 www.aacr.org 51 Infarct 51 YONDELIS 51 Announce Merger Agreement 51 Advant e Corporation 51 Apoptone 51 TriMas Corporation Announces 51 mitogen activated ERK kinase 51 Visit CompuMed 51 www.amvescap.com 51 Virulizin ® 51 visit www.globalrailway.com 51 Uterine Fibroid Embolization 51 KRN# 51 telomerase inhibitor drug 51 please visit http:/www.sunesis.com 51 Psychiatry Clin Neurosci 51 logging onto www.gtc 51 Cachexia 51 www.asco.org 51 PXD# 51 INFO ON 51 StockSource.us Reports 51 5q MDS 51 METHOD FOR 51 Revises FY# Outlook 51 www.cellceutix.com 51 J Virol 51 BRIM3 51 information visit www.mda.gov.sg 51 Nexavar prescribing 51 Inc. NASDAQ HEPH 51 Psychopharmacol 51 THAT ARE DIFFICULT TO 51 BioLife Solutions 51 info@endeca.com 51 BioProcess International 51 Initiated Phase 51 Phase Ib II 51 www.stemcellsinc.com 51 www.QuestDiagnostics.com 51 Biomarkers 51 Vevo LAZR system 51 pertuzumab 51 FUTURE EVENTS 51 Inc. Nasdaq BNVI 51 NASDAQ ASTM Methode 51 NANOTECH 51 BIOCOM Investor Conference 51 Breast Ultrasound 51 papillary renal cell carcinoma 51 TNFerade TM 51 canbe accessed 51 antiproliferative effects 51 Nucleic Acids Res 51 CSI OTCBB CSWI 51 TO PATIENTS 51 OMP #M# 51 www.genome.gov 51 IN NATURE 51 Jennifer Convertibles Reports 51 Arch Surg 51 Analytical Methods 51 Thallion Announces 51 OR Live.com Presents 51 Gastrointestinal Cancers Symposium 51 RTI Biologics Announces 51 news subscribe.htm 51 www.rxipharma.com 51 STRATEGY FOR AN OPEN 51 AMERISAFE Announces 51 http:/www.radian.biz 51 Xenonics Announces 51 http:/www.AMCORE.com 51 www.intrusion.com 51 #rd Annual CTRC 51 worsening thrombocytopenia 51 Symposium SABCS 51 www.jaguarmining.com 51 Viad Corp Announces 51 YEAR END RESULTS CONFERENCE 51 Gynecol Oncol 51 including eniluracil ADH 51 Upcoming Investor Events 51 CCR5 mAb 51 www.financialdisclosure.ca 51 TRANSFORMS 51 Clinical Trial Enrollment 51 http:/www.skystarbio-pharmaceutical.com 51 www.gsk.com 51 IDEXX Laboratories Announces 51 www.cmdiagnostics.com 51 http:/www.ovonic.com/ 51 RNA antagonists 51 www.bio.org 51 Carcinogenesis 51 www.addexpharma.com 51 #:#-# [032] 51 MIND CTI LTD 51 Renal Cell Carcinoma RCC 51 EORTC NCI AACR 51 Clin Oncol 51 Growing Importance 51 crizotinib PF # 51 Bakers Footwear Reports 51 DESIGNED TO 51 Biodesix 51 MelaFind R 51 Taping Results SPOILERS 51 Refractory Angina 51 #st Annual Meeting 51 Avicena 51 X# HER SISTER 51 http:/www.reprosrx.com 51 Xelox 51 abnormal p# 51 Clinical Dermatology 51 Threshold Pharmaceuticals Announces 51 Phase III placebo controlled 51 Imprime PGG ® 51 PROSTVAC TM 51 CRLX# 51 Astralis Ltd. 51 www.dctindustrial.com 51 http:/www.caliperLS.com 51 www.charlesandcolvard.com 51 Synalloy Corporation Announces 51 www.gtc bio.com 51 www.ariad.com 51 ir@crucell.com www.crucell.com 51 http:/www.alexza.com 51 Clinical Oncology Annual Meeting 51 PI3 kinase inhibitors 51 www.methylgene.com 51 Symadex 51 NASDAQ ARRY 50 abstracts summarizing 50 Clinicaltrials.gov 50 http:/www.icadmed.com 50 Multiple Ascending Dose 50 ADVERSE REACTIONS 50 www.igate.com 50 www.achillion.com 50 Sono Tek Announces 50 www.makosurgical.com 50 Prostate AdenoCarcinoma Treatment 50 Abstract Free Full Text 50 www.calypto.com 50 http:/www.gene.com/ 50 Initiate Phase II 50 Cancer iSBTc 50 www.kontron.com 50 www.itmag.com 50 ChemGenex Pharmaceuticals Limited 50 www.cardiome.com 50 Regeneron Announces 50 KEMET Announces 50 http:/www.mhihospitality.com 50 QuadraSphere 50 www.bruker.com 50 Arch Dis Child 50 ixabepilone 50 NYMAGIC INC. Reports 50 www.anthera.com 50 Zix Corporation Announces 50 http:/www.torreypinestherapeutics.com 50 antitumor effects 50 PROSTVAC VF 50 Orckit Communications Reports 50 OTCBB PVSP 50 HemaCare Reports 50 http:/www.celgene.com 50 E CENP E 50 myocardial infarction ventricular fibrillation 50 Vascugel ® 50 Adtegrity.com Reports 50 www.aixtron.com 50 CLINICAL TRIALS 50 www.resverlogix.com 50 Nasdaq ENZN 50 NASDAQ Listing Requirements 50 Am J Epidemiol 50 ASTEROID 50 J Natl Cancer Inst 50 Cholesterol Levels SPARCL 50 abstr 50 www.hanmifinancial.com 50 Valhi Reports 50 Zenvia Phase III